Lv1
60 积分 2022-09-27 加入
Metronomic chemotherapy and breast cancer: a critical evaluation of its role in the new landscape of therapeutics
2天前
已完结
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer
2天前
已完结
Trastuzumab Deruxtecan in HER2-Positive Breast Cancer with HER2 Loss After Dual-Target Adjuvant Therapy: A Case Report
1个月前
已关闭
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer
2个月前
已完结
Systemic treatment for hormone receptor-positive/HER2-negative advanced/metastatic breast cancer: A review of European real-world evidence studies
6个月前
已完结
Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors
6个月前
已完结
The PARTNER trial of neoadjuvant olaparib in triple-negative breast cancer
7个月前
已完结
PARP Inhibitors for Breast Cancer Treatment
7个月前
已完结
Incidence of antibody–drug conjugate-related fatigue in patients with breast cancer: A systematic review and meta-analysis
7个月前
已完结
Efficacy and safety of trastuzumab deruxtecan in treating human epidermal growth factor receptor 2-low/positive advanced breast cancer: a meta-analysis of randomized controlled trials
7个月前
已完结
皖公网安备34019202002308
